AKTS analyst estimates
Aktis Oncology (AKTS) analyst ratings, the average price target and its range, and every firm's latest call.
AKTS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 9, 2026 | Oppenheimer | Aktis Oncology initiated with an Outperform at Oppenheimer | $40.00 |
| Aug 19, 2026 | Wedbush | Aktis Oncology initiated with an Outperform at Wedbush | $35.00 |
| Aug 18, 2026 | BMO Capital | Aktis Oncology initiated with an Outperform at BMO Capital | $37.00 |
| Jun 15, 2026 | Raymond James | Aktis Oncology initiated with a Strong Buy at Raymond James | $40.00 |
| Jun 2, 2026 | H.C. Wainwright | Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright | $35.00 |
| Mar 9, 2026 | H.C. Wainwright | Aktis Oncology initiated with a Buy at H.C. Wainwright | $30.00 |
| Feb 3, 2026 | Leerink Partners | Aktis Oncology initiated with an Outperform at Leerink | $31.00 |
- 8 firms rate AKTS: 8 buy, 0 hold, 0 sell.
- The average price target is $37.40 from 5 analysts, from $35.00 to $40.00.
Updated 2026-11-03 11:32 UTC